Artiva Biotherapeutics (ARTV) said Monday it highlighted clinical, safety and translational data for AlloNK presented at the European Alliance of Associations for Rheumatology 2026 Congress.
The company said presentations across rheumatoid arthritis, Sjogren disease and systemic sclerosis highlighted AlloNK's potential to induce deep B-cell depletion and meaningful clinical responses in refractory patients.
The company said rheumatoid arthritis data showed a 71% ACR50 response rate at six months in patients in its Phase 2a basket trial.
Artiva said the US Food and Drug Administration's Regenerative Medicine Advanced Therapy designation for AlloNK in combination with rituximab provides an expedited development pathway as it advances its planned Phase 3 program in refractory rheumatoid arthritis.
Shares of the company were up 3.7% in premarket trading.